Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment
Pharmaceuticals · 06.08.2026 · 19 (8) · 1239
DOI: 10.3390/ph19081239 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmaceuticals, online erschienen am 06.08.2026. Verfasst von Bojana Milašinović und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia.
Abstract (Originalsprache)
Background/Objectives: The safety profile of adalimumab in inflammatory bowel disease (IBD) has been established in clinical trials, but post-marketing surveillance remains important for detecting rare and late-onset adverse events (AEs). This study aimed to evaluate long-term safety and temporal dynamics of AEs in an IBD cohort treated with adalimumab, and to identify potential safety signals using the FDA Adverse Event Reporting System (FAERS).
Methods
This retrospective single-center study included patients with IBD treated with adalimumab. Demographic, clinical, and treatment-related data, including AEs and newly identified extraintestinal manifestations (EIMs), were collected. Time-to-event (TTE) analyses were used to assess AEs temporal patterns and covariates associated with onset. FAERS disproportionality analysis was performed for cohort-identified AEs and EIMs.
Results
A total of 217 patients with 591.29 patient-years (PYs) of exposure (up to 9.62 years) were included. AE incidence was 106.6/100 PY. Time to first AE was described using the Kaplan–Meier method, and additionally the Weibull distribution, with an estimated median time of 11.4 months (95% CI: 9.7–13.5). The most frequent AEs were infections (32.30/100 PY), hepatic events (9.98/100 PY), and cutaneous manifestations (8.46/100 PY), characterized by TTE analysis. Serious outcomes, including malignancies and demyelinating events, were rare. Several unlisted MedDRA preferred terms, including infectious, cutaneous, vascular, proliferative, and musculoskeletal events, emerged as FAERS signals.
Conclusions
This study provides long-term real-world evidence supporting the established safety profile of adalimumab in IBD. First AEs occurred throughout treatment exposure with lower hazard over time. Isolated FAERS signals, including vascular occlusive events, may warrant further investigation and continued pharmacovigilance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
- Department of Gastroenterology and Hepatology, Zvezdara University Medical Center, 11000 Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
ORCID-Profile: Srđan Marković, Petar Svorcan, Branislava Miljković, Katarina Vučićević
Förderung
- Science Fund of the Republic of Serbia
Zitieren
APA
Milašinović, B., Marković, S., Vezmar Kovačević, S., Svorcan, P., Miljković, B., & Vučićević, K. (2026). Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment. Pharmaceuticals, 19(8), 1239. https://doi.org/10.3390/ph19081239
Vancouver
Milašinović B, Marković S, Vezmar Kovačević S, Svorcan P, Miljković B, Vučićević K. Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment. Pharmaceuticals. 2026;19(8):1239. doi:10.3390/ph19081239
BibTeX
@article{Milainovi2026,
author = {Milašinović, Bojana and Marković, Srđan and Vezmar Kovačević, Sandra and Svorcan, Petar and Miljković, Branislava and Vučićević, Katarina},
title = {Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1239},
doi = {10.3390/ph19081239}
}
EUVIMED